Synta CEO resigns

Synta Pharmaceuticals' (SNTA) president & CEO, Safi R. Bahcall, has resigned effective immediately.

A newly formed executive committee will run the business until a successor is hired.

The company discloses no reasons for Dr. Bahcall's departure.

The firm has been an underperformer for more than a year. Shares are down 48% since last February.

Mutual fund ownership has eroded from 176 to 133 over the past 4 quarters.

From other sites
Comments (2)
  • JoeMRI
    , contributor
    Comments (54) | Send Message
    Did he deliver? Or he's going to comprtition.
    3 Mar 2014, 06:56 PM Reply Like
  • joelkatz
    , contributor
    Comments (570) | Send Message

    3 Mar 2014, 07:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs